Sorafenib before liver transplantation for hepatocellular carcinoma: Risk or give up

Transplant International

Volumn 24, Issue 11, 2011, Pages

  Di Benedetto, Fabrizio ^a   Tarantino, Giuseppe ^a   Montalti, Roberto ^a   Ballarin, Roberto ^a   D'Amico, Giuseppe ^a   Berretta, Massimiliano ^b   Gerunda, Giorgio Enrico ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CANCER TRANSPLANTATION; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; KIDNEY GRAFT REJECTION; LETTER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; PYRIDINES;

EID: 80053999294     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01329.x     Document Type: Letter

References (5)

1. Truesdale AE, Caldwell SH, Shah NL, et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011; 24: 991.
2. Di Benedetto F, Berretta M, De Ruvo N, et al. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? J Surg Oncol 2011; doi:.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378.
4. Semela D, Dufour JF,. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864.
5. Wood LS,. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006; 3: 558.